Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 483
Titolo Tipologia Data di pubblicazione Autori File
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results 01 - Articolo su rivista 2025 Colombo N. +
Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer 01 - Articolo su rivista 2025 Colombo N. +
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial 01 - Articolo su rivista 2025 Colombo, Nicoletta +
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma 01 - Articolo su rivista 2025 Colombo N. +
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status: Clinical Studies 01 - Articolo su rivista 2025 Colombo N. +
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety 01 - Articolo su rivista 2025 Colombo N. +
Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer 01 - Articolo su rivista 2025 Colombo N. +
Systems epigenetic approach towards non-invasive breast cancer detection 01 - Articolo su rivista 2025 Colombo N. +
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer 01 - Articolo su rivista 2025 Colombo N. +
External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer 01 - Articolo su rivista 2025 Gaeta, AFumagalli, DColombo, N +
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation 01 - Articolo su rivista 2025 Colombo N. +
Uterine leiomyosarcoma 01 - Articolo su rivista 2025 Colombo N. +
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study 01 - Articolo su rivista 2025 Colombo N. +
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 01 - Articolo su rivista 2025 Colombo N. +
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study 01 - Articolo su rivista 2025 Colombo N. +
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201 01 - Articolo su rivista 2025 Colombo N. +
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study 01 - Articolo su rivista 2025 Colombo N. +
Quantitative Proteomics and Phosphoproteomics Analysis of Patient-Derived Ovarian Cancer Stem Cells 01 - Articolo su rivista 2025 Colombo N. +
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial 01 - Articolo su rivista 2025 Colombo N. +
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer 01 - Articolo su rivista 2025 Colombo N. +
Mostrati risultati da 1 a 20 di 483
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile